Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiploma Regulatory News (DPLM)

Share Price Information for Diploma (DPLM)

Share Price is delayed by 15 minutes
Get Live Data
7,130.00    80.00 (1.13%)
Bid:
7,110.00
Ask:
7,120.00
Spread: 10.00 (0.141%)
Market Cap: £9.56b
DPLM Live PriceLast checked at - London Stock Exchange

Intraday Diploma Share Chart

Interim Management Statement

14 Jan 2009 07:00

RNS Number : 5894L
Diploma PLC
14 January 2009
Β 

ο»Ώ

<>

12 CHARTERHOUSE SQUARE,Β LONDONΒ EC1M 6AX

TELEPHONE: +44 (0)20 7549 5700

FACSIMILE: +44 (0)20Β 7549 5715

FOR IMMEDIATE RELEASE

14Β January 2009

DIPLOMA PLC

INTERIM MANAGEMENT STATEMENT

Diploma PLC, the international group of businessesΒ supplyingΒ specialisedΒ technicalΒ products and services,Β is todayΒ issuingΒ its first Interim Management StatementΒ of the new financial year,Β aheadΒ of the Company's AGM to be held today atΒ Brewers Hall,Β Aldermanbury Square,Β London, EC2V 7HR atΒ 12.00Β midday. ThisΒ Statement relates to the period from 1 October 2008Β to 31 December 2008Β and includes the first quarter's trading.

TheΒ Group continues toΒ benefitΒ from its focus onΒ specialised sectors and supplyingΒ essential products and servicesΒ which areΒ mostlyΒ funded by customers' operating, rather than capital,Β budgets.Β Β With more than 60% of revenues generated outside theΒ UK, the Group has alsoΒ gainedΒ on translationΒ fromΒ the significant deterioration in the value ofΒ UKΒ sterling relative to all other major currencies. With this background, the Board is able to report an increase inΒ GroupΒ revenues of 2%Β overΒ the comparable period last yearΒ although,Β on a constant currency basis,Β GroupΒ revenues reduced by 7% over the comparable period.

In Life Sciences, the CanadianΒ HealthcareΒ businesses, which account for over 50% of sector revenue,Β continued to show steadyΒ development.Β Β Revenue from the European businessesΒ were somewhat reducedΒ againstΒ a strong comparable quarter last year.

TradingΒ inΒ the USΒ SealsΒ businessesΒ weakenedΒ in the quarter,Β reflectingΒ the difficultΒ marketΒ conditionsΒ in theΒ broaderΒ USΒ industrialΒ economy. Cost reduction programmes implemented in theΒ USΒ operations have partly mitigated the effects of reduced operational leverage. By contrast, the performance of theΒ European Seals businessesΒ was strong.

In Controls,Β the European businessesΒ overallΒ delivered a steady performance,Β with a continuedΒ focus on relatively more buoyant, technically driven sectors.Β 

The deterioration in the value ofΒ UKΒ sterling relative toΒ allΒ other major currencies has had a significantΒ positiveΒ impact onΒ the Group's results on translation. Against the comparable period last year, the US dollar,Β the EuroΒ and the Canadian dollarΒ have appreciated by 25%,Β 16%Β and 6%Β respectively againstΒ UKΒ sterling. Conversely at a transaction level,Β the weakness ofΒ UKΒ sterling and the deterioration of the Canadian dollar relative to the US dollar,Β hasΒ put pressure on gross marginsΒ in theΒ UKΒ and Canadian businesses, by increasing the cost of goods sold.

The Group continuedΒ to maintain a strong financial position with cash balances of Β£16.6m at 31 December 2008 and undrawn committed term facilities of Β£25.0m.

On 23 December 2008, the Group announced that it hadΒ signed contracts to acquireΒ RT/Dygert,Β a leading supplier of seals, o-rings and custom moulded and machine parts, based in theΒ US, for a maximum consideration of Β£13.2m (US$19.75m). This acquisition formally closed onΒ 12Β January 2009 andΒ theΒ initial consideration paid of Β£9.6m (US$14.4m) has been funded in part from the Group's existing cash resources and in part by drawing down Β£4.7m (US$7.0m) from the Group'sΒ committedΒ bank facility. This acquisition is expected to be immediately earnings enhancing for the Group.

In addition, as reported in the 2008 Annual Report, on 5 November 2008, the Group acquired Meditech, a small medical diagnostic company inΒ CanadaΒ for a maximum consideration of Β£1.5m (C$2.9m). On completion, the initial considerationΒ ofΒ Β£1.3m (C$2.4m) was funded out of the Group's existing cash resources.

Finally, pursuant to theΒ sale andΒ purchaseΒ agreement signed on 28 August 2007, theΒ Group will shortly be making a paymentΒ to the vendors of AMTΒ of Β£1.1m (C$2.0m)Β asΒ deferredΒ consideration. This payment wasΒ based on the performance of that business during the year ended 30 September 2008.

There have been no other significant changes in the position of the Group in the period since the publication of the Annual Report for the year ended 30 September 2008.

The next update on trading is expected to be issued as part of the Half Year results for the six months ending 31 March 2009, which are expected to be released on 11 May 2009.

Notes:

This Interim Management Statement,Β which is based upon unaudited management accounts, has been prepared solely to provide additional information to the shareholders of Diploma PLC in order to meet the requirements of theΒ UKΒ Listing Authority's Disclosure and Transparency Rules. It should not be relied on by any other party, for other purposes.

A copy of this Statement, together withΒ furtherΒ information about DiplomaΒ PLC, may be viewed on its websiteΒ atΒ www.diplomaplc.com

For further enquiries please contact:

Bruce Thompson, Chief Executive Officer

020 7549 5700

Nigel Lingwood, Group Finance Director

020 7549 5705

Simon Bloomfield, Bankside Consultants

020 7367 8861

NOTE TO EDITORS:

Diploma PLCΒ is an international group of businesses supplyingΒ specialisedΒ technical products and services to the Life Sciences, Seals and Controls industries.

Diploma achieves stable growth and attractive margins from its focus on supplying specialised technical products to markets which value high levels of customer service, technical support and value adding activities. A high proportion of revenues are generated from essential products and services funded by operating, rather than capital budgets.

The Group employs ca. 1,000 employees and its principal operating businesses are located in theΒ UK,Β Germany, US andΒ Canada.

Over the last five years, the Group has grown adjusted earnings per share at an average of ca. 21% p.a. through a combination of organic growth and acquisitions. The current market capitalisation is ca. Β£150m.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSEAXFDFSFNEFE
Date   Source Headline
9th Dec 20154:00 pmRNSAnnual Financial Report and Notice of AGM
30th Nov 201510:00 amRNSHolding(s) in Company
17th Nov 201510:00 amRNSDirectorate Change
16th Nov 20157:00 amRNSFinal Results
27th Oct 201512:10 pmRNSHolding(s) in Company
30th Sep 20159:31 amRNSDirector/PDMR Shareholding
25th Sep 201510:01 amRNSDirector/PDMR Shareholding
24th Sep 20159:12 amRNSHolding(s) in Company
24th Sep 20159:00 amRNSHolding(s) in Company
23rd Sep 20154:50 pmRNSDirector/PDMR Shareholding
14th Sep 201511:43 amRNSHolding(s) in Company
8th Sep 20157:00 amRNSDirectorate Changes
3rd Sep 20153:00 pmRNSDirector/PDMR Shareholding
2nd Sep 20157:02 amRNSDirectorate Change
2nd Sep 20157:00 amRNSTrading Update
24th Aug 20159:47 amRNSHolding(s) in Company
24th Aug 20157:00 amRNSHolding(s) in Company
10th Jul 20157:00 amRNSNotice of Trading Update
5th Jun 201511:00 amRNSDirector Declaration
14th May 20154:00 pmRNSDirector/PDMR Shareholding
11th May 20157:00 amRNSInterim Management Statement
31st Mar 201510:04 amRNSDirector/PDMR Shareholding
30th Mar 20157:00 amRNSTrading Statement
13th Mar 20157:00 amRNSAcquisition
27th Feb 20157:00 amRNSDirectorate Change
10th Feb 20157:00 amRNSAppointment of Non-Executive Director
5th Feb 20154:00 pmRNSDirector/PDMR Shareholding
27th Jan 20155:28 pmRNSHolding(s) in Company
21st Jan 20155:00 pmRNSResult of AGM
21st Jan 20154:42 pmRNSDirectorate Change
21st Jan 20157:00 amRNSTrading Statement
5th Dec 20144:00 pmRNSAnnual Financial Report and Notice of AGM
27th Nov 20141:28 pmRNSHolding(s) in Company
25th Nov 20144:00 pmRNSDirector/PDMR Shareholding
17th Nov 20147:00 amRNSPreliminary Announcement of Results
12th Nov 20147:00 amRNSDirectorate Change
7th Oct 20147:00 amRNSAcquisition
29th Sep 20147:00 amRNSTrading Statement
17th Sep 20143:24 pmRNSHolding(s) in Company
9th Sep 201410:04 amRNSDirector/PDMR Shareholding
22nd Aug 20149:41 amRNSHolding(s) in Company
30th Jul 20147:00 amRNSInterim Management Statement
3rd Jul 201410:04 amRNSDirector/PDMR Shareholding
3rd Jul 20149:26 amRNSHolding(s) in Company
19th Jun 201412:00 pmRNSHolding(s) in Company
13th Jun 20149:46 amRNSHolding(s) in Company
22nd May 20149:44 amRNSHolding(s) in Company
12th May 20147:00 amRNSHalf Yearly Report
28th Apr 201410:00 amRNSNotice of 2014 Half Year Results
17th Apr 20144:44 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.